What's happening
Isomorphic Labs, the AI drug discovery company spun out of Alphabet's Google DeepMind, is in advanced discussions to raise more than $2 billion in a new funding round led by Thrive Capital with participation from Alphabet. The funding round has not yet closed and will support the company's AI-powered drug design capabilities and global expansion efforts.
This represents a significant increase from Isomorphic Labs' first funding round of $600 million completed in March 2025, which was also led by Thrive Capital with participation from GV and Alphabet. The company has established partnerships with major pharmaceutical companies including Johnson & Johnson, Eli Lilly, and Novartis to leverage its AI-driven drug discovery platform.
Why it matters for markets
The $2 billion funding round positions Alphabet at the forefront of the AI-biotech convergence, potentially adding significant value to its $4.86 trillion market capitalization through its stake in Isomorphic Labs. With Alphabet trading at a P/E ratio of 30.6 and generating $422.50 billion in revenue, this investment represents a strategic expansion beyond its core communication services into the high-growth pharmaceutical AI sector.
The funding demonstrates substantial investor appetite for AI-powered drug discovery platforms, with the round size more than tripling from the $600 million raised just over a year ago. For pharmaceutical partners, this capital infusion could accelerate drug development timelines and reduce research costs, potentially impacting companies like Johnson & Johnson with its $96.36 billion revenue base, Eli Lilly's $72.25 billion revenue stream, and Novartis' $56.58 billion in annual sales.
The AI drug discovery market's growth trajectory is reflected in the valuations of partner companies, with Eli Lilly commanding a market cap of $845.77 billion and trading at 33.7 times earnings, while Johnson & Johnson maintains a $532.77 billion valuation at 25.6 times earnings, and Novartis holds a $278.64 billion market cap at 20.9 times earnings.
Sectors and assets to watch
Alphabet (GOOGL) stands to benefit directly from the funding round through its participation and ownership stake in Isomorphic Labs, potentially enhancing its position in the AI-healthcare intersection beyond its traditional search and cloud computing dominance. The company's stock has gained 0.71% and trades near its 52-week high of $402.00.
Pharmaceutical partners Johnson & Johnson (JNJ), Eli Lilly (LLY), and Novartis (NVS) could see operational benefits from enhanced AI drug discovery capabilities. Johnson & Johnson, down 0.53% and trading well below its 52-week high of $251.71, could leverage the platform for its Innovative Medicine segment. Eli Lilly, despite a 2.72% decline, maintains strong positioning in diabetes and obesity treatments that could benefit from AI-enhanced drug development. Novartis, up 0.44%, could apply the technology across its oncology and precision medicine portfolio.
What to watch next
Monitor the completion of Isomorphic Labs' $2 billion funding round and any announcements regarding specific drug development programs or expanded partnerships with the three pharmaceutical companies. Track quarterly earnings reports from Alphabet, Johnson & Johnson, Eli Lilly, and Novartis for updates on AI drug discovery investments and their impact on research and development expenses and pipeline advancement timelines.